Cargando…
A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering
A “universal” platform that can rapidly generate multiplex vaccine candidates is critically needed to control pandemics. Using the severe acute respiratory syndrome coronavirus 2 as a model, we have developed such a platform by CRISPR engineering of bacteriophage T4. A pipeline of vaccine candidates...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442874/ https://www.ncbi.nlm.nih.gov/pubmed/34516878 http://dx.doi.org/10.1126/sciadv.abh1547 |
_version_ | 1783753082953269248 |
---|---|
author | Zhu, Jingen Ananthaswamy, Neeti Jain, Swati Batra, Himanshu Tang, Wei-Chun Lewry, Douglass A. Richards, Michael L. David, Sunil A. Kilgore, Paul B. Sha, Jian Drelich, Aleksandra Tseng, Chien-Te K. Chopra, Ashok K. Rao, Venigalla B. |
author_facet | Zhu, Jingen Ananthaswamy, Neeti Jain, Swati Batra, Himanshu Tang, Wei-Chun Lewry, Douglass A. Richards, Michael L. David, Sunil A. Kilgore, Paul B. Sha, Jian Drelich, Aleksandra Tseng, Chien-Te K. Chopra, Ashok K. Rao, Venigalla B. |
author_sort | Zhu, Jingen |
collection | PubMed |
description | A “universal” platform that can rapidly generate multiplex vaccine candidates is critically needed to control pandemics. Using the severe acute respiratory syndrome coronavirus 2 as a model, we have developed such a platform by CRISPR engineering of bacteriophage T4. A pipeline of vaccine candidates was engineered by incorporating various viral components into appropriate compartments of phage nanoparticle structure. These include expressible spike genes in genome, spike and envelope epitopes as surface decorations, and nucleocapsid proteins in packaged core. Phage decorated with spike trimers was found to be the most potent vaccine candidate in animal models. Without any adjuvant, this vaccine stimulated robust immune responses, both T helper cell 1 (T(H)1) and T(H)2 immunoglobulin G subclasses, blocked virus-receptor interactions, neutralized viral infection, and conferred complete protection against viral challenge. This new nanovaccine design framework might allow the rapid deployment of effective adjuvant-free phage-based vaccines against any emerging pathogen in the future. |
format | Online Article Text |
id | pubmed-8442874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84428742021-09-24 A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering Zhu, Jingen Ananthaswamy, Neeti Jain, Swati Batra, Himanshu Tang, Wei-Chun Lewry, Douglass A. Richards, Michael L. David, Sunil A. Kilgore, Paul B. Sha, Jian Drelich, Aleksandra Tseng, Chien-Te K. Chopra, Ashok K. Rao, Venigalla B. Sci Adv Biomedicine and Life Sciences A “universal” platform that can rapidly generate multiplex vaccine candidates is critically needed to control pandemics. Using the severe acute respiratory syndrome coronavirus 2 as a model, we have developed such a platform by CRISPR engineering of bacteriophage T4. A pipeline of vaccine candidates was engineered by incorporating various viral components into appropriate compartments of phage nanoparticle structure. These include expressible spike genes in genome, spike and envelope epitopes as surface decorations, and nucleocapsid proteins in packaged core. Phage decorated with spike trimers was found to be the most potent vaccine candidate in animal models. Without any adjuvant, this vaccine stimulated robust immune responses, both T helper cell 1 (T(H)1) and T(H)2 immunoglobulin G subclasses, blocked virus-receptor interactions, neutralized viral infection, and conferred complete protection against viral challenge. This new nanovaccine design framework might allow the rapid deployment of effective adjuvant-free phage-based vaccines against any emerging pathogen in the future. American Association for the Advancement of Science 2021-09-08 /pmc/articles/PMC8442874/ /pubmed/34516878 http://dx.doi.org/10.1126/sciadv.abh1547 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Zhu, Jingen Ananthaswamy, Neeti Jain, Swati Batra, Himanshu Tang, Wei-Chun Lewry, Douglass A. Richards, Michael L. David, Sunil A. Kilgore, Paul B. Sha, Jian Drelich, Aleksandra Tseng, Chien-Te K. Chopra, Ashok K. Rao, Venigalla B. A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering |
title | A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering |
title_full | A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering |
title_fullStr | A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering |
title_full_unstemmed | A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering |
title_short | A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering |
title_sort | universal bacteriophage t4 nanoparticle platform to design multiplex sars-cov-2 vaccine candidates by crispr engineering |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442874/ https://www.ncbi.nlm.nih.gov/pubmed/34516878 http://dx.doi.org/10.1126/sciadv.abh1547 |
work_keys_str_mv | AT zhujingen auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT ananthaswamyneeti auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT jainswati auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT batrahimanshu auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT tangweichun auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT lewrydouglassa auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT richardsmichaell auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT davidsunila auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT kilgorepaulb auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT shajian auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT drelichaleksandra auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT tsengchientek auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT chopraashokk auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT raovenigallab auniversalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT zhujingen universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT ananthaswamyneeti universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT jainswati universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT batrahimanshu universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT tangweichun universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT lewrydouglassa universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT richardsmichaell universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT davidsunila universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT kilgorepaulb universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT shajian universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT drelichaleksandra universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT tsengchientek universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT chopraashokk universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering AT raovenigallab universalbacteriophaget4nanoparticleplatformtodesignmultiplexsarscov2vaccinecandidatesbycrisprengineering |